

Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center

TAP TO RETURN TO KIOSK MENU



Rationale

- · Well established that breast MRI detects more disease and impacts surgical management
- Not known whether by detecting additional disease:
 - Rates of local failure are reduced
 - Rates of contralateral breast cancer are decreased
- Breast MRI may be particularly important for ER/PR negative disease which is shown to be relatively radio-resistant with higher rates of local failure after BCT
 - Detecting and surgically removing additional foci of disease may be particularly important for this group of patients.

Hypothesis

Preoperative breast MRI improves staging and selection of patients with hormone receptor negative tumors for BCT, thus lowering rates of local regional recurrence.

Rationale

Objective

Study Schema

FAQs

Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster



Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center





Trial Endpoints

Primary

· LRR rates at 5 years between the MRI and no MRI arm

Secondary

- · Rates of re-excision, including conversion to mastectomy
- · Contralateral breast cancer rates
- Time to local recurrence
- · Overall and disease specific survival
- MRI technical performance (sensitivity, specificity, PPV)

Rationale

Trial Endpoints

Study Schema

FAQs

Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster



Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center



Study Schema



A program of the National Cancer Institute of the National Institutes of Health

Trial Endpoints
Study Schema

FAQs


Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster





Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center



Study Schema



Rationale

Trial Endpoints

Study Schema

FAQs

Key Eligibility Criteria


Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster

For Enrollment After Neoadjuvant Chemotherapy





Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center





Frequently Asked Questions (FAQs)

Trial Endpoints

Study Schema

Rationale

FAQs

Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster

BRCA testing

- Not required to enroll
- If pt. referred for testing, can still enroll into trial. If later found to be BRCA +, can come off study.

MRI reimbursement

- For patients randomized to MRI arm, additional \$900 will be paid by ACRIN to support image data collection and transmission
- MRI can be billed to insurance as per institutional guidelines/standards

Is prior history of contralateral breast cancer an exclusion?

- Yes

Can Spanish speaking patients enroll?

 Yes, Spanish forms available for all aspects except "Assessment of Survivor Concerns" form which will require translation to patient

Is there a patient education brochure?

 Yes, available on Alliance website and on the CTSU website



Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center



Key Eligibility Criteria



Rationale
Trial Endpoints
Study Schema
FAQs

Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster · Women with

- ER/PR <10%
- Any Her2
- Stage I-II, unilateral cancer
- · No previous breast cancer history
- · Preoperative chemotherapy is allowed
- · No plans for partial breast irradiation following lumpectomy
- No known BRCA carriers
- No breast MRI in the 12 months prior to enrollment



Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center



Accrual By Site



A program of the National Cancer Institute of the National Institutes of Health


Rationale
Trial Endpoints
Study Schema
FAQs


Key Eligibility Criteria

Accrual By Site

Accrual By Month Follow Up

Please use the headings above to navigate through the different sections of the poster





accrual data is through 09/30/2019



Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center





A program of the National Cancer Institute of the National Institutes of Health

Accrual By Month

Rationale Trial Endpoints Study Schema FAQs


Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster



accrual data is through 09/30/2019



Isabelle Bedrosian, MD

University of Texas MD Anderson Cancer Center

TAP TO RETURN TO KIOSK MENU

Funding Support



Rationale
Trial Endpoints
Study Schema
FAQs

Key Eligibility Criteria

Accrual By Site

Accrual By Month

Follow Up

Please use the headings above to navigate through the different sections of the poster

Alliance A011104 is funded by the National Institutes of Health through National Cancer Institute grant awards.

Contact Us

Study Chair: Isabelle Bedrosian, MD, University of Texas MD Anderson Cancer Center

E-mail: ibedrosian@mdanderson.org | Phone: 713-792-3245

Protocol Coordinator: Laura Hoffman

E-mail: hoffma12@uchicago.edu | Phone: 773-834-2546